

Excluded EAA assessment reports

Common name	Therapeutic area	ATC	Prioritization date*	Reason for exclusion [#]
rifaximin	Hepatic encephalopathy	A07AA11	2012-08-24	Not EMA
selexipag	Hypertension, Pulmonary	B01AC27	2015-10-07	After study period
dabigatran etexilate	Atrial Fibrillation	B01AE07	2009-11-11	Indication extension
rivaroxaban	Atrial Fibrillation	B01AF01	2012-03-13	Indication extension
rivaroxaban	Deep Vein Thrombosis; Pulmonary Embolism	B01AF01	2012-04-18	Indication extension
rivaroxaban	Acute Coronary Syndrome	B01AF01	2012-08-24	Indication extension
apixaban	Atrial Fibrillation	B01AF02	2012-03-13	Indication extension
ivabradine	Chronic Heart Failure	C01EB17	2012-01-31	Indication extension
tolvaptan	Inappropriate ADH Syndrome	C03XA01	2010-09-29	Before study period
tadalafil	Benign Prostatic Hyperplasia	G04BE08	2012-09-25	Indication extension
dutasteride	Prostatic Neoplasms	G04CB02	2011-04-5	Indication extension
dasabuvir / ombitasvir / paritaprevir / ritonavir	Hepatitis C, Chronic	J05AP52	2014-11-12	After study period ^s
paclitaxel	Pancreatic Neoplasms	L01CD01	2013-12-9	Indication extension
bevacizumab	Ovarian Neoplasms	L01XC07	2011-11-2	Indication extension
ramucirumab	Colorectal Neoplasms	L01XC21	2015-09-30	Indication extension
ramucirumab	Carcinoma, Non-Small-Cell Lung	L01XC21	2015-10-13	Indication extension
nivolumab	Carcinoma, Non-Small-Cell Lung	L01XC17	2015-06-25	Indication extension
necitumumab	Carcinoma, Non-Small-Cell Lung	L01XC22	2015-10-13	After study period

everolimus	Breast Neoplasms	L01XE10	2012-10-18	Indication extension
osimertinib	Carcinoma, Non-Small-Cell Lung	L01XE35	2015-12-16	After study period
abiraterone acetate	Prostatic Neoplasms	L02BX03	2013-01-16	Indication extension
eculizumab	Hemoglobinuria, Paroxysmal	L04AA25	2010-12-22	Before study period
tofacitinib	Arthritis, Rheumatoid	L04AA29	2012-10-22	After study period
daclizumab	Multiple Sclerosis	L04AC01	2015-10-22	After study period
lesinurad	Hyperuricemia	M04AB05	2015-12-02	After study period
tapentadol	Pain	N02AX06	2010-12-22	Not EMA
cannabinoids	Multiple Sclerosis	N02BG10	2012-04-20	Not EMA
quetiapine	Depressive Disorder, Major	N05AH04	2010-07-12	Indication extension
quetiapine	Anxiety Disorders	N05AH04	2010-09-16	Indication extension
indacaterol	Pulmonary Disease, Chronic Obstructive	R03AC18	2010-05-12	Before study period
pegaptanib	Macular Edema; Diabetes Complications	S01LA03	2011-05-20	Indication extension
ranibizumab	Macular Edema; Diabetes Complications	S01LA04	2010-10-27	Indication extension
ranibizumab	Central Retinal Vein Occlusion	S01LA04	2011-09-06	Indication extension

ATC anatomical therapeutic chemical; EAA early awareness and assessment; EMA European Medicines Agency

*Date of EAA assessment report

#'Before (after) study period' refers to when the medicine was processed by EMA

§Withdrawn by manufacturer